An official website of the United States government
Report your review integrity concerns. Report your concerns about unfair review. Learn more about integrity & fairness in review.
Small Business: Small Molecule Therapeutic Development for Alzheimer’s Disease, Related Dementias and Neurodegenerative Disorders – NPB (10)
Dr. Kathryn Partlow
Scientific Review Officer
This review panel reviews applications dealing with basic and clinical aspects of drug discovery in treatment of aging and neurodegenerative disorders, including mild-cognitive impairment, Alzheimer’s disease and related dementias, movement degenerative disorders such as Parkinson’s, Huntington’s, amyotrophic lateral sclerosis. Approaches are those of medicinal chemistry and pre-clinical development, toxicology, and some clinical studies to establish proof-of-principle for new or repurposing existing drugs. The therapeutic formats studied in NPB 10 focus on small molecule drugs.
Topics
- Interventions for senescence of nerve cells, cognitive aging, and mild cognitive impairment (MCI)
- Alzheimer’s disease (AD)
- Alzheimer’s related dementia (ADRD) including frontotemporal dementia (FTD), Lewy body dementia (LBD), Limbic-predominant age-related TDP-43 encephalopathy (LATE), and Creutzfeldt-Jakob disease (CJD)
- Neurodegenerative movement disorders such as Parkinson’s diseases (PD), essential tremor, ataxia, Huntington’s disease (HD), amyotrophic lateral sclerosis (ALS), spinal muscular atrophy (SMA), etc.
- Approaches utilized include small molecule development, medicinal chemistry, pK/pD and toxicology studies.
- The range of studies include target identification, target validation, and target optimization in in vitro/ex vivo, pre-clinical as well as proof of principle early stage clinical studies.